FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1036697783> ?p ?o ?g. }

• W1036697783 abstract "Abstract Introduction: Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by accelerated platelet destruction and inadequate platelet production mediated by autoantibodies. As there are no specific diagnostic tests, the diagnosis of ITP remains one of exclusion. Although the incidence of ITP increases with age, there are no practice guidelines for elderly patients and few studies have been conducted. Compared with younger patients, older patients have a higher incidence of serious bleeding complications and increased related mortality. Therefore we propose to describe our experience in the management of ITP in patients over 65 years old. Methods: We conducted a retrospective study of 44 patients over 65 years old at the moment of the ITP diagnosis, treated in our center from January 1995 to March 2014. Variables analyzed were age, Charlson score, clinical manifestations and platelet count at diagnosis, type of treatment, response to treatment and adverse events. Results: The median current age is 77 years (IQR, 70-84 years), with a median age at diagnosis of 69 years (IQR, 65-75 years). The ratio of males to females was 0.91. Eighteen (40.9%) patients had a Charlson score greater than or equal to 2. The comorbilities were 27.8% diabetes with damage to target organs; 11.4% coronary disease; 9.8% solid metastatic tumor, 9.8% peripheral vascular disease, 9.8% chronic pulmonary disease; 5% congestive heart failure, 5% peptic ulcer, 5% cerebrovascular disease, 5% moderate-severe liver disease, 5% moderate-severe renal disease y 1.6% connective tissue disease, 1.6% dementia, 1.6% hemiplegia and 1.6% leukemia. The mean platelet count at diagnosis was 28x109 / L (IQR, 8-74x109 / L). Initial presentation was thrombocytopenia on a routine blood count in 43% of patients while the rest presented bleeding symptoms. Fourteen patients (31.8%) required admission on diagnosis. 18.8% showed major bleeding: 6 (13.63%) gastrointestinal haemorrhages, 1 (2.2%) hematuria and 47.7% minor bleeding: 8 (18.18%) bruising, 7 (15.9%) mucosal bleeding and 7 (15.89%) purpura and epistaxis. Regarding treatment, observation was used in 11 patients (25%), all of whom subsequently acheived spontaneous remission. Corticosteroid therapy (prednisone 0.5-1mg/kg), was the initial treatment used in 13 patients (29.5%), 15.9% received intravenous inmunoglobulins (1gr/kg x 2 days) and 18.2% combination therapy. A response was obtained in 75.6% of patients (35.6% CR, 40% R). Seven (16%) subjects received second-line treatment (1 splenectomy, 3 romiplostim, 1 eltrombopag, 1 rituximab, 1 Imurel). The patient that underwent splenectomy obtained CR. Of the 3 patients treated with romiplostim, 2 achieved CR directly, and the third required rescue therapy with eltrombopag to reach CR. The patient that received second line treatment with eltrombopag obtained R and the patient treated with Rituximab failed and needed rescue therapy with romiplostim. Finally the patient treated with azathioprine is in CR but still on treatment. At present we have an 84.1% response rate after a median follow up of 66 months (IQR, 27-100 months). During treatment we observed a single vascular event in the form of deep vein thrombosis with associated pulmonary embolism in a subject with additional thromboembolic risk factors. We found no infections, hyperglycemia or hypertensive crisis which required hospital admission or special monitoring. Five patients (11.4%) developed neoplasms (hepatocellular carcinoma, rectal neoplasm, pancreatic adenocarcinoma and Hürthle cell carcinoma), none of which were haematological. Three patients died: 2 due to neoplasm progression and 1 to acute renal failure. Conclusions: Low and intermediate doses of corticosteroids are a good first line treatment option in elderly patients. Close monitoring of the patient is advisable to ensure the early detection and treatment of adverse events and possible underlying diseases that could justify the thrombocytopenia. In our series the incidence of major bleeding in over 65s with ITP is clearly superior to that reported in younger subjects. Therefore, it is essential to optimize the intensity and duration of treatment in these patients. Disclosures No relevant conflicts of interest to declare." @default.
• W1036697783 created "2016-06-24" @default.
• W1036697783 creator A5009241499 @default.
• W1036697783 creator A5011385333 @default.
• W1036697783 creator A5035815404 @default.
• W1036697783 creator A5086096928 @default.
• W1036697783 date "2014-12-06" @default.
• W1036697783 modified "2023-09-28" @default.
• W1036697783 title "Primary Immune Thrombocytopenia in Elderly Patients: Clinical Profile, Efficacy and Safety of Treatment Protocols" @default.
• W1036697783 doi "https://doi.org/10.1182/blood.v124.21.4196.4196" @default.
• W1036697783 hasPublicationYear "2014" @default.
• W1036697783 type Work @default.
• W1036697783 sameAs 1036697783 @default.
• W1036697783 citedByCount "1" @default.
• W1036697783 countsByYear W10366977832020 @default.
• W1036697783 crossrefType "journal-article" @default.
• W1036697783 hasAuthorship W1036697783A5009241499 @default.
• W1036697783 hasAuthorship W1036697783A5011385333 @default.
• W1036697783 hasAuthorship W1036697783A5035815404 @default.
• W1036697783 hasAuthorship W1036697783A5086096928 @default.
• W1036697783 hasConcept C120665830 @default.
• W1036697783 hasConcept C121332964 @default.
• W1036697783 hasConcept C126322002 @default.
• W1036697783 hasConcept C141071460 @default.
• W1036697783 hasConcept C167135981 @default.
• W1036697783 hasConcept C197934379 @default.
• W1036697783 hasConcept C2779134260 @default.
• W1036697783 hasConcept C61511704 @default.
• W1036697783 hasConcept C71924100 @default.
• W1036697783 hasConceptScore W1036697783C120665830 @default.
• W1036697783 hasConceptScore W1036697783C121332964 @default.
• W1036697783 hasConceptScore W1036697783C126322002 @default.
• W1036697783 hasConceptScore W1036697783C141071460 @default.
• W1036697783 hasConceptScore W1036697783C167135981 @default.
• W1036697783 hasConceptScore W1036697783C197934379 @default.
• W1036697783 hasConceptScore W1036697783C2779134260 @default.
• W1036697783 hasConceptScore W1036697783C61511704 @default.
• W1036697783 hasConceptScore W1036697783C71924100 @default.
• W1036697783 hasLocation W10366977831 @default.
• W1036697783 hasOpenAccess W1036697783 @default.
• W1036697783 hasPrimaryLocation W10366977831 @default.
• W1036697783 hasRelatedWork W1981495890 @default.
• W1036697783 hasRelatedWork W2015178853 @default.
• W1036697783 hasRelatedWork W2023714324 @default.
• W1036697783 hasRelatedWork W2037118506 @default.
• W1036697783 hasRelatedWork W2145689774 @default.
• W1036697783 hasRelatedWork W2171485542 @default.
• W1036697783 hasRelatedWork W2265244168 @default.
• W1036697783 hasRelatedWork W2344864653 @default.
• W1036697783 hasRelatedWork W2402867541 @default.
• W1036697783 hasRelatedWork W2550972357 @default.
• W1036697783 hasRelatedWork W2557771723 @default.
• W1036697783 hasRelatedWork W2570601088 @default.
• W1036697783 hasRelatedWork W2578771497 @default.
• W1036697783 hasRelatedWork W2588636762 @default.
• W1036697783 hasRelatedWork W2616824453 @default.
• W1036697783 hasRelatedWork W2982178284 @default.
• W1036697783 hasRelatedWork W3033247738 @default.
• W1036697783 hasRelatedWork W3136287534 @default.
• W1036697783 hasRelatedWork W3199264943 @default.
• W1036697783 hasRelatedWork W45760047 @default.
• W1036697783 isParatext "false" @default.
• W1036697783 isRetracted "false" @default.
• W1036697783 magId "1036697783" @default.
• W1036697783 workType "article" @default.